Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 12, 2024, serves as a transaction notification for the month of August 2024. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| 2024-08-09 | Ordinary Shares (ISIN: GB00BN7SWP63) | £15.5067 | 16 Shares (8 partnership + 8 matching) | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine compliance notifications for executive share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Executives Involved: The filing covers transactions by eight senior executives, including CEO Emma Walmsley, CFO Julie Brown, and Company Secretary Victoria Whyte.
- Transaction Nature: All transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership and matching shares.
- Uniformity: Every listed executive executed the exact same transaction volume (16 shares) at the identical price (£15.5067) on the same date (August 9, 2024).
- Financial Impact: The total value of these specific transactions is negligible relative to the company's overall market capitalization.